Abivax S.A. American Depositary Receipt (2X10)
XSTU 
NASDAQ (NMS) Primary XSTU Summary
2X10 Chart
Alger Mid Cap Growth Fund Q4 2025 Portfolio Update
Class A shares of the Alger Mid Cap Growth Fund outperformed the Russell Midcap Growth Index during the fourth quarter of 2025. Cidara Therapeutics, Inc., Natera, Inc., and Abivax were among the top contributors to performance. Roblox Corp. Class A, e.l.f. Beauty, Inc., and Nebius Group were among the top detractors from performance.
Abivax CEO dismisses 'noise' around rumored Eli Lilly bid
Abivax Chief Executive Marc de Garidel dismissed as "noise" reports in the French press that pharmaceutical giant Eli Lilly may take over his company, and said market speculation about an ongoing review by French authorities was inconsistent with how French foreign-investment oversight works.
Abivax: Don't Just Buy The Rumor, Buy The Fundamentals
Abivax (ABVX) remains a Buy, driven by obefazimod's strong UC data and significant multi-billion dollar market potential. ABVX is a credible M&A target, with Eli Lilly and other pharma giants rumored as potential acquirers, but fundamentals—not acquisition hopes—should drive investment decisions. Key 2026 catalysts include Phase 3 UC maintenance topline data, potential NDA/MAA filings, and Phase 2B Crohn's disease results.
Abivax S.A. American Depositary Receipt (2X10) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has Abivax S.A. American Depositary Receipt ever had a stock split?
Abivax S.A. American Depositary Receipt Profile
| Biotechnology Industry | Healthcare Sector | Marc de Garidel CEO | XSTU Exchange | US00370M1036 ISIN |
| FR Country | 69 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
ABIVAX Société Anonyme operates in the forefront of biotechnology with a focus on discovering and developing therapeutic solutions aimed at modulating the body's natural immune response. Founded in 2013 and with its headquarters in Paris, France, this clinical-stage company is dedicated to addressing chronic inflammatory diseases through innovative treatments. By leveraging the body's own regulatory mechanisms, ABIVAX aims to provide effective and potentially pioneering therapies for diseases that currently have limited treatment options.
Products and Services
- Obefazimod:
As the lead drug candidate of ABIVAX, obefazimod represents a significant advancement in the treatment of chronic inflammatory diseases. Currently, it is undergoing Phase 3 clinical trials for its efficacy against moderately to severely active ulcerative colitis in adults. This therapeutic approach underscores ABIVAX’s commitment to tackling unmet medical needs within the realm of inflammatory diseases through the utilization of the body's inherent mechanisms for restoring immune balance.
